Toxicity Profiles of Systemic Therapies for Advanced Hepatocellular Carcinoma A Systematic Review and Meta-analysis

被引:14
作者
Griffiths, Christopher D. [1 ]
Zhang, Betty [2 ]
Tywonek, Kasia [1 ]
Meyers, Brandon M. [3 ,4 ]
Serrano, Pablo E. [1 ,4 ,5 ]
机构
[1] McMaster Univ, Dept Surg, Hamilton, ON, Canada
[2] Univ Ottawa, Dept Anesthesia, Ottawa, ON, Canada
[3] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[4] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[5] Juravinski Hosp, Div Gen Surg, 711 Concess St,B3 Off 161, Hamilton, ON L8V 1C3, Canada
关键词
RANDOMIZED PHASE-II; DOUBLE-BLIND; LIVER-TRANSPLANTATION; 2ND-LINE TREATMENT; 1ST-LINE THERAPY; TRANSARTERIAL CHEMOEMBOLIZATION; SORAFENIB TREATMENT; PLUS BEVACIZUMAB; OPEN-LABEL; PLACEBO;
D O I
10.1001/jamanetworkopen.2022.22721
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE The recent development of targeted therapy and immunotherapy has made neoadjuvant therapy an attractive option for patients with hepatocellular carcinoma (HCC). However, surgeons are concerned that adverse effects of neoadjuvant therapy with these agents could lead to delayed or even cancelled surgeries. OBJECTIVE To summarize the current evidence regarding toxicity profiles for tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) among patients with HCC. DATA SOURCES Medline, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from January 1990 and December 2021. STUDY SELECTION Single-group, placebo-controlled, and dual-agent clinical trials comparing TKIs and ICIs in patients with HCC were eligible for inclusion. DATA EXTRACTION AND SYNTHESIS Following the Preferred Reporting Items in Systematic Reviews and Meta-analysis guideline, 2 reviewers independently extracted data. A random-effects model was used. MAIN OUTCOMES AND MEASURES The primary outcome was the proportion of patients with clinically significant liver-related adverse events. Secondary outcomes included the proportion of patients who experienced clinically relevant (grade 3 or higher) adverse events and significant adverse events (ie, those that were life threatening, required hospitalization, or prolonged disability) as well as the risk ratio (RR) of these complications. RESULTS Overall, 30 studies with 12 921 patients were included. Patients had a mean (range) age of 62 (18-89) years; a mean (SD) 84%(3) were male; a mean (SD) 82%(16) had Barcelona Clinic Liver Cancer stage C HCC; and a mean (SD) 97%(6) had Childs A cirrhosis. Overall, 21% (95% CI, 16%-26%) of patients receiving TKIs had liver toxic effects compared with 28%(95% CI, 21%-35%) of patients receiving ICIs. Severe adverse events occurred in 46%(95% CI, 40%-51%) of patients receiving TKIs compared with 24%(95% CI, 13%-35%) of patients receiving ICIs. Compared with patients receiving sorafenib, other TKIs were associated with similar rates of liver toxic effects (RR, 1.06; 95% CI, 0.92-1.24) but higher rates of severe adverse events (RR, 1.24; 95% CI, 1.07-1.44). Comparing ICIs with sorafenib, there were similar rates of liver toxic effects (RR, 1.10; 95% CI, 0.86-1.40) and severe adverse events (RR, 1.19; 95% CI, 0.95-1.50). CONCLUSIONS AND RELEVANCE In this systematic review and meta-analysis, serious adverse events were lower with ICIs than with TKIs, while liver toxic effects were similar. Combination therapy with novel ICIs is an appealing option in trials of neoadjuvant therapy for patients with HCC, requiring evaluation in preoperative trials.
引用
收藏
页数:14
相关论文
共 60 条
  • [1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
    Abou-Alfa, G. K.
    Meyer, T.
    Cheng, A. -L.
    El-Khoueiry, A. B.
    Rimassa, L.
    Ryoo, B. -Y.
    Cicin, I.
    Merle, P.
    Chen, Y. H.
    Park, J. -W.
    Blanc, J. -F.
    Bolondi, L.
    Klumpen, H. -J.
    Chan, S. L.
    Zagonel, V.
    Pressiani, T.
    Ryu, M. -H.
    Venook, A. P.
    Hessel, C.
    Borgman-Hagey, A. E.
    Schwab, G.
    Kelley, R. K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) : 54 - 63
  • [2] Abreu P., 2019, CURR HEPATOL REP, V18, P400, DOI [10.1007/s11901-019-00492-y, DOI 10.1007/S11901-019-00492-Y]
  • [3] Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma
    Akateh, Clifford
    Black, Sylvester M.
    Conteh, Lanla
    Miller, Eric D.
    Noonan, Anne
    Elliott, Eric
    Pawlik, Timothy M.
    Tsung, Allan
    Cloyd, Jordan M.
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (28) : 3704 - 3721
  • [4] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
    Bruix, Jordi
    Qin, Shukui
    Merle, Philippe
    Granito, Alessandro
    Huang, Yi-Hsiang
    Bodoky, Gyrogy
    Pracht, Marc
    Yokosuka, Osamu
    Rosmorduc, Olivier
    Breder, Valeriy
    Gerolami, Rene
    Masi, Gianluca
    Ross, Paul J.
    Song, Tianqiang
    Bronowicki, Jean-Pierre
    Ollivier-Hourmand, Isabelle
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Llovet, Josep M.
    Finn, Richard S.
    LeBerre, Marie-Aude
    Baumhauer, Annette
    Meinhardt, Gerold
    Han, Guohong
    [J]. LANCET, 2017, 389 (10064) : 56 - 66
  • [5] Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
    Cainap, Calin
    Qin, Shukui
    Huang, Wen-Tsung
    Chung, Ik Joo
    Pan, Hongming
    Cheng, Ying
    Kudo, Masatoshi
    Kang, Yoon-Koo
    Chen, Pei-Jer
    Toh, Han-Chong
    Gorbunova, Vera
    Eskens, Ferry A. L. M.
    Qian, Jiang
    McKee, Mark D.
    Ricker, Justin L.
    Carlson, Dawn M.
    El-Nowiem, Saied
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (02) : 172 - U77
  • [6] Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
    Cheng, Ann-Lii
    Hsu, Chiun
    Chan, Stephen L.
    Choo, Su-Pin
    Kudo, Masatoshi
    [J]. JOURNAL OF HEPATOLOGY, 2020, 72 (02) : 307 - 319
  • [7] Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
    Cheng, Ann-Lii
    Thongprasert, Sumitra
    Lim, Ho Yeong
    Sukeepaisarnjaroen, Wattana
    Yang, Tsai-Shen
    Wu, Cheng-Chung
    Chao, Yee
    Chan, Stephen L.
    Kudo, Masatoshi
    Ikeda, Masafumi
    Kang, Yoon-Koo
    Pan, Hongming
    Numata, Kazushi
    Han, Guohong
    Balsara, Binaifer
    Zhang, Yong
    Rodriguez, Ana-Marie
    Zhang, Yi
    Wang, Yongyu
    Poon, Ronnie T. P.
    [J]. HEPATOLOGY, 2016, 64 (03) : 774 - 784
  • [8] Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study
    Cheng, Ann-Lii
    Kang, Yoon-Koo
    He, Aiwu Ruth
    Lim, Ho Yeong
    Ryoo, Baek-Yeol
    Hung, Chao-Hung
    Sheen, I-Shyan
    Izumi, Namiki
    Austin, TaShara
    Wang, Qiang
    Greenberg, Jonathan
    Shiratori, Shinichi
    Beckman, Robert A.
    Kudo, Masatoshi
    [J]. JOURNAL OF HEPATOLOGY, 2015, 63 (04) : 896 - 904
  • [9] Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.
    Cheng, Ann-Lii
    Yen, Chia-Jui
    Kim, Tae-You
    Feng, Yin-Hsun
    Chao, Yee
    Lin, Deng-Yn
    Loembe, Arsene-Bienvenu
    Hocke, Julia
    Choi, Caren
    Ryoo, Baek-Yeol
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [10] Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
    Cheng, Ann-Lii
    Kang, Yoon-Koo
    Lin, Deng-Yn
    Park, Joong-Won
    Kudo, Masatoshi
    Qin, Shukui
    Chung, Hyun-Cheol
    Song, Xiangqun
    Xu, Jianming
    Poggi, Guido
    Omata, Masao
    Lowenthal, Susan Pitman
    Lanzalone, Silvana
    Yang, Liqiang
    Lechuga, Maria Jose
    Raymond, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) : 4067 - +